LOS ANGELES, CA--(Marketwire - October 11, 2010) -
Ritter Pharmaceuticals, Inc. (http://www.ritterpharmaceuticals.com/
), a biological therapeutics company with a focus on digestive diseases, won the grand prize and audience favorite awards in the Tech Coast Angels' 4th annual Quick Pitch Competition. The Quick Pitch Competition featured 14 finalists who each gave a brief presentation on their business investment opportunity in front of a panel of industry judges and an audience of over 500 leaders within the entrepreneurial community.
CEO Andrew Ritter focused his presentation on the company's flagship product, RP-G28, which is being developed as the first prescription drug to treat lactose intolerance long-term. His presentation not only won the grand prize, but also overwhelmingly won the audience popular vote. "This was a great opportunity to share our vision," said Ritter. "The positive feedback we received from the audience reflects the broad interest in new treatments for lactose intolerance, a condition that afflicts as many as 80 million people in North America and 4.3 billion internationally."
During his presentation, Ritter shared his personal story of suffering from lactose intolerance and how the condition dramatically affected his health and lifestyle. He described how living with lactose intolerance motivated him to found Ritter Pharmaceuticals to seek a solution and to help the millions of others who also suffer from the condition. Currently, there is no effective or fully reliable treatment available for lactose intolerance. Ritter also discussed the future possibilities for RP-G28, saying "I look forward to taking RP-G28 through clinical trials and hope our product will one day improve the lives of sufferers around the world."
About Lactose Intolerance
Lactose intolerance is the inability to digest dairy products, such as milk, ice cream, cheese and pizza. Symptoms include a combination of digestive discomfort including gas, cramping, bloating or diarrhea. Beyond the painful, uncomfortable and embarrassing gastrointestinal consequences, the disease can increase the long-term health risks for osteoporosis, hypertension, and certain cancers, including colon and breast.
Lactose intolerance represents a large and underpenetrated global market. A unique mechanism of action gives RP-G28 the potential to be the only therapeutic regimen designed to impact the natural factors of the disease and alleviate the symptoms of lactose intolerance on a long-term basis. Following FDA acceptance of an Investigational New Drug (IND) application for RP-G28, Ritter Pharmaceuticals is prepared to begin Phase 2 clinical development.
About Ritter Pharmaceuticals:
Ritter Pharmaceuticals is committed to the discovery, development and commercialization of innovative therapeutic treatments for gastrointestinal diseases. The Company's scientific platform of gastrointestinal physiology, metabolism and gut adaptation brings creativity to providing unique therapeutic approaches to a variety of GI diseases, including lactose intolerance, irritable bowel syndrome, Crohn's disease, and ulcerative colitis. Ritter's mission is to help individuals live a healthier and happier lifestyle through improving one's digestion and overall well-being.